Nalaganje...
Targeting the JAK2-STAT5 pathway in CML
In this issue of Blood, Gallipoli et al show that combined targeting of BCR/ABL1 and Janus kinase 2 (JAK2) by 2 established kinase inhibitors, nilotinib (NI) and the JAK1/2 kinase inhibitor ruxolitinib (RUX), results in synergistic growth inhibition in immature CD34(+) stem and progenitor cells obta...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4148757/ https://ncbi.nlm.nih.gov/pubmed/25170113 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-585943 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|